News Release Detail

June 7, 2002

Mylan Signs Licensing Agreement With 3M Pharmaceuticals

Mylan Signs Licensing Agreement With 3M PharmaceuticalsPITTSBURGH, Jun 7, 2002 (BUSINESS WIRE) -- Mylan Laboratories Inc. (NYSE: MYL) announced today that it has reached an agreement with 3M Pharmaceuticals for an exclusive supply and distribution agreement to sell Flecainide Acetate Tablets in bottles of 100 of the 50 mg, 100 mg and 150 mg strengths.

In addition, UDL Laboratories, Inc., a Mylan subsidiary, will be shipping Flecainide Acetate to the institutional marketplace in unit dose strips (10 X 10's) for the 50 mg and 100 mg strengths.

Mylan Flecainide Acetate is therapeutically equivalent to 3M Pharmaceuticals Tambocor® Tablets. Tambocor is a $110 million brand and is indicated as an antiarrhythmic.

The launch of Mylan labeled Flecainide Acetate is another important addition to our growing line and strengthens Mylan's position as a leader in the generic drug industry.

Mylan Laboratories Inc., is a leading pharmaceutical company that develops, manufacturers and markets generic and proprietary prescription pharmaceutical products. The company markets an extensive line of generic products through three business units, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., and UDL Laboratories, Inc. and branded products through its Bertek Pharmaceuticals Inc. subsidiary. For more information, visit

To the extent any statements made in this release contain information that is not historical, these statements are essentially forward-looking statements regarding our anticipated financial results and estimates, business prospects and products in research and under going development, all of which involve substantial risks and uncertainties. Such risks and uncertainties are not predictable or quantifiable; consequently, should known or unknown risks or uncertainties materialize, or should our assumptions or estimates prove inaccurate, actual results could differ materially from those expressed or implied by such forward-looking statement. For further details and a discussion of such risks and uncertainties, we encourage you to read Forward-looking Statements found in our Annual Report on Form 10-K for the fiscal year ended March 31, 2001, and in our periodic reports on Forms 10-Q and 8-K (if any).

We assume no obligation to update any forward-looking statements presented here today, whether as a result of new information, future events or otherwise.

Mylan Laboratories Inc.

CONTACT:          Mylan Laboratories Inc.
                  Patricia Sunseri, 412/232-0100

(c) 2002 Business Wire. All reproduction, other than for an individual user`s reference, is prohibited without prior written permission.
Email Alerts
Investor FAQs
Contact Us